Two Penguins Investment
Preparing your financial briefing…
Financial Intelligence
Recent perspective
Recent financial reporting selected by recency, stored importance, and source diversity.
Live chronology
Page 411 · Newest reporting first
Nasdaq Marketscompaniesroutine announcement
Altria Group declared its 61st dividend increase in 57 years. The article calculates annual income from a $10,000 investment.
Nasdaq Marketscommoditiesmarket event
Gas turbine prices are on track to nearly triple, boosting stocks like GE Vernova. The article highlights the surge in prices.
CNBC Top Newscompaniesinvestment opinion
Morgan Stanley analysts suggest that Meta's product pipeline could start flowing following a legal clearing event. The settlement may pave the way for new AI product launches.
CNBC Top Newsmarketsmarket event
Treasury yields continued to climb on Wednesday as inflation fears stoked a global rise in borrowing costs. The global bond sell-off persists.
Nasdaq Marketsmarketsmarket event
European stocks were subdued near a one-month low on Wednesday. Concerns over rising oil prices and bond yields weighed on sentiment.
Channel NewsAsia Businessmarketsmarket event
Stocks rose after recent declines, while the Japanese yen jumped against the US dollar. This indicates a shift in market sentiment and currency movements.
Channel NewsAsia Businessmarketsmarket event
Stocks fell and bond yields rose as the U.S. and Iran exchanged attacks. The escalation heightened risk aversion and deepened the bond rout.
Channel NewsAsia Businessmarketsmarket event
Stocks fell and the bond rout deepened as the US and Iran traded attacks. The escalation heightened geopolitical risk and pressured risk assets.
Nasdaq Marketsmarketsinvestment opinion
Stretched AI valuations, heavy concentration, leverage, and circular financing are identified as real risks in September. The article discusses whether AI stock investors should be worried.
Nasdaq Marketscompaniesinvestment opinion
Argenx's top and bottom lines are growing robustly, with 18 consecutive quarters of sales growth. The article questions whether the biotech stock remains underrated.